Aerami Therapeutics is a clinical stage biopharmaceutical company based in San Francisco, CA, specializing in the development of innovative inhaled therapies for the treatment of cardiopulmonary conditions. Leveraging their proprietary inhalation technology, they are committed to opening new pathways for patients with cardiopulmonary diseases through precision drug delivery.
With a focus on developing differentiated drug-device combination products, Aerami Therapeutics is advancing a range of inhaled therapies, including AER-901 for pulmonary arterial hypertension, AER-601 for Type 2 diabetes, and AER-501 for both Type 1 and Type 2 diabetes. Their dedication to improving the lives of patients is evident through their clinical trials and collaborations with leading healthcare professionals and organizations.
Generated from the website